Grifols (MEX:GRF N) 3-Month Share Buyback Ratio : 0.00% (As of Dec. 2024 )

View and export this data going back to 2023. Start your Free Trial

What is Grifols 3-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Grifols's current 3-Month Share Buyback Ratio was 0.00%.

Competitive Comparison of Grifols's 3-Month Share Buyback Ratio

For the Drug Manufacturers - General subindustry, Grifols's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grifols's 3-Month Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Grifols's 3-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Grifols 3-Month Share Buyback Ratio Calculation

Grifols's 3-Month Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

3-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Sep. 2024 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Sep. 2024 )
	=	(680.409	-	680.409)	/	680.409
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols (MEX:GRF N) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Grifols 3-Month Share Buyback Ratio Related Terms

Grifols Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (MEX:GRF N) » Definitions » 3-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFLF:USA GRFS:USA 1GRF:Italy GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany G0F0:Germany OZTA:Germany OZTA:Germany G0FB:Germany GRF:Austria

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Grifols Headlines

No Headlines